Early postimplantation embryolethality in mice following in utero inhibition of adenosine deaminase with 2′-deoxycoformycin
- 1 December 1989
- journal article
- research article
- Published by Wiley in Teratology
- Vol. 40 (6) , 615-626
- https://doi.org/10.1002/tera.1420400609
Abstract
Adenosine deaminase (ADA) catalyzes the hydrolytic deamination of adenosine (or 2′‐deoxyadenosine) to inosine (or 2′‐deoxyinosine). Previously, we have shown that ADA activity is subject to strong cell‐specific developmental regulation in placental tissues of mice between days 6 and 11 of gestation (Knudsen et al.:Biology of Reproduction 39:937–951, 1988). In the present study, we examined the effects of intrauterine exposure to 2′‐deoxycoformycin (dCF; pentostatin), a potent irreversible inhibitor of ADA, on early postimplantation development. Deoxycoformycin was administered to pregnant ICR mice as a single intraperitoneal injection at a dose of 5 mg/kg on one of days 6 through 11 of gestation (plug day 0). A marked increase in the incidence of implantation site resorptions was observed following treatment specifically on days 7 (61% resorbed) or 8 (78% resorbed). No effect was observed following treatment on days 6, 9, 10, or 11. ADA‐immunoreactive protein was shown, by ABC‐immunoperoxidase staining on days 7 or 8 of gestation, to be present at high levels in decidual cells of the antimesometrial region but at below‐detectable levels in the embryo. Treatment of pregnant dams with dCF on day 7 produced a complete (>99%) inhibition of ADA activity in the antimesometrial decidua by 30 min, induced excessive cell death in the prospective neural plate and primary mesenchyme of the trilaminar disc by 6 h, and arrested embryonic development at an early somite stage. These results suggest that the antimesometrial decidua plays a protective role in preventing an inappropriate accumulation of endogenous ADA substrates in the implantation site.This publication has 31 references indexed in Scilit:
- Evidence for negative control of growth by adenosine in the mammalian embryo: Induction of Hmx/+ mutant limb outgrowth by adenosine deaminaseDifferentiation, 1987
- Immune Function in Mice Exposed to the Adenosine Deaminase Inhibitor 2'-Deoxycoformycin During Immune System DevelopmentImmunopharmacology and Immunotoxicology, 1987
- Inherited enzyme deficiencies and immunodeficiency: Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficienciesClinical Immunology and Immunopathology, 1986
- Association of Adenosine Deaminase with Differentiation of Normal and Leukemic T and B LymphocytesaAnnals of the New York Academy of Sciences, 1985
- Thymocyte Differentiation and ADA InhibitionAnnals of the New York Academy of Sciences, 1985
- Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2′-deoxycoformycin, an adenosine deaminase inhibitorClinical Immunology and Immunopathology, 1981
- Adenosine deaminase inhibitors: Differential effects on multiple forms of adenosine deaminaseBiochemical and Biophysical Research Communications, 1978
- INHIBITION OF ADENOSINE DEAMINASE BY CO-VIDARABINE AND ITS EFFECT ON THE METABOLIC DISPOSITION OF ADENINE ARABINOSIDE (VIDARABINE)Annals of the New York Academy of Sciences, 1977
- Variation in Placental Adenosine Deaminase Activity During Gestation1Biology of Reproduction, 1970
- Some substrates and inhibitors of adenosine deaminaseBiochimica et Biophysica Acta (BBA) - Enzymology and Biological Oxidation, 1965